QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Incyte
(NASDAQ:INCY)
74.34
00
At close: May 19
74.34
00
After Hours: 4:22PM EDT
Day High/Low- - -
52 Week High/Low61.91 - 88.26
Open / Close- / -
Float / Outstanding182.6M / 221.5M
Vol / Avg.- / 1.5M
Mkt Cap16.5B
P/E17.7
50d Avg. Price77.23
Div / Yield-
Payout Ratio-
EPS0.17
Total Float182.6M

Incyte (NASDAQ:INCY), Quotes and News Summary

Incyte (NASDAQ: INCY)

Day High/Low- - -
52 Week High/Low61.91 - 88.26
Open / Close- / -
Float / Outstanding182.6M / 221.5M
Vol / Avg.- / 1.5M
Mkt Cap16.5B
P/E17.7
50d Avg. Price77.23
Div / Yield-
Payout Ratio-
EPS0.17
Total Float182.6M
Benzinga - Sponsored
Benzinga - 6 days ago
Benzinga - May 11, 2022, 8:33AM
Benzinga - May 5, 2022, 9:20AM
Benzinga - May 5, 2022, 5:17AM
Benzinga - May 4, 2022, 7:56AM
Benzinga - May 4, 2022, 5:13AM
Benzinga - May 3, 2022, 2:05PM
Benzinga - May 3, 2022, 10:45AM
Benzinga - May 3, 2022, 7:28AM
Benzinga - May 3, 2022, 7:27AM
Benzinga - May 2, 2022, 9:23AM
Benzinga - Apr 28, 2022, 4:09PM
Benzinga - Apr 22, 2022, 12:00PM
Benzinga - Apr 22, 2022, 9:41AM
Benzinga - Apr 20, 2022, 10:36AM
Benzinga - Mar 28, 2022, 10:12AM
Benzinga - Mar 28, 2022, 7:59AM
Benzinga - Mar 25, 2022, 8:31AM
Benzinga - Mar 23, 2022, 7:05AM
Benzinga - Mar 18, 2022, 9:56AM
Benzinga - Mar 14, 2022, 11:15AM
Benzinga - Mar 14, 2022, 8:01AM
Benzinga - Mar 11, 2022, 7:21AM
load more
Sector: Health Care.Industry: Biotechnology
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-02
REV
Q1 2022Est.ActualSurprise
EPS0.6800.550 -0.1300
REV750.660M733.235M-17.425M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Incyte Questions & Answers

Q
How do I buy Incyte (INCY) stock?
A

You can purchase shares of Incyte (NASDAQ: INCY) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Incyte's (INCY) competitors?
Q
What is the target price for Incyte (INCY) stock?
A

The latest price target for Incyte (NASDAQ: INCY) was reported by Morgan Stanley on Thursday, May 5, 2022. The analyst firm set a price target for 77.00 expecting INCY to rise to within 12 months (a possible 3.58% upside). 16 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Incyte (INCY)?
A

The stock price for Incyte (NASDAQ: INCY) is $74.34 last updated May 19, 2022, 8:00 PM UTC.

Q
Does Incyte (INCY) pay a dividend?
A

There are no upcoming dividends for Incyte.

Q
When is Incyte (NASDAQ:INCY) reporting earnings?
A

Incyte’s Q2 earnings are confirmed for Tuesday, August 2, 2022.

Q
Is Incyte (INCY) going to split?
A

There is no upcoming split for Incyte.

Q
What sector and industry does Incyte (INCY) operate in?
A

Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.